A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Autoimmune Diseases
Abroad (travel likely)RecruitingPHASE1
Conditions
Healthy · Idiopathic Inflammatory Myopathies · Systemic Sclerosis · Sjögren's Disease
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Xencor Investigative Site, Melbourne, Australia
Study leads
Mark Osterman, MD, MSCE
Study Director
Xencor, Inc.